DNA Repair Drugs Market

DNA damage leads to the incorporation of defects and aberrations in the genome that often result in functional mutations. When these mutations occur in genes coding for vital proteins and/or enzymes, it leads to the development of genetic diseases. However, our biological system is equipped with a robust repair mechanism capable of correcting damaged DNA sequences. PARP inhibitors and other similar therapeutics are designed to augment the body?s innate DNA repair mechanism and aid in the treatment of diseases associated with genetic aberrations.

DNA Repair Drugs Market contains market size and forecasts of DNA Repair Drugs in global, including the following market information:

Global DNA Repair Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global DNA Repair Drugs Market Sales, 2017-2022, 2023-2028, (K Units)

Global top five DNA Repair Drugs companies in 2021 (%)

The global DNA Repair Drugs market was valued at 610.8 million in 2021 and is projected to reach US$ 1901.1 million by 2028, at a CAGR of 17.6% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

PARP Inhibitors Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of DNA Repair Drugs include 4SC AG, ARCAGY/ GINECO GROUP, Bristol Myers Squibb, British Columbia Cancer Agency, Cambridge University Hospitals NHS Foundation Trust, Genentech, Georgetown University, German Breast Group and GlaxoSmithKline, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the DNA Repair Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global DNA Repair Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global DNA Repair Drugs Market Segment Percentages, by Type, 2021 (%)

PARP Inhibitors

Other

Global DNA Repair Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global DNA Repair Drugs Market Segment Percentages, by Application, 2021 (%)

Oncological

Stroke

Global DNA Repair Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global DNA Repair Drugs Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies DNA Repair Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies DNA Repair Drugs revenues share in global market, 2021 (%)

Key companies DNA Repair Drugs sales in global market, 2017-2022 (Estimated), (K Units)

Key companies DNA Repair Drugs sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

4SC AG

ARCAGY/ GINECO GROUP

Bristol Myers Squibb

British Columbia Cancer Agency

Cambridge University Hospitals NHS Foundation Trust

Genentech

Georgetown University

German Breast Group

GlaxoSmithKline

Jiangsu Hengrui Medicine

Johnson & Johnson

Jonsson Comprehensive Cancer Center

Karyopharm Therapeutics

KuDOS Pharmaceuticals

National Health Service

National Institutes of Health

Tesaro